These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19021608)

  • 1. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?
    Schroeck FR; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2009 Mar; 103(5):603-8. PubMed ID: 19021608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.
    Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    Urology; 2013 Jul; 82(1):53-8. PubMed ID: 23806388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.
    Schroeck FR; Kattan MW; Moul JW; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Sun L; Freedland SJ
    BJU Int; 2010 Jun; 105(12):1654-9. PubMed ID: 19912203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
    Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database.
    Freedland SJ; Vidal AC; Howard LE; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ;
    Cancer; 2017 Nov; 123(21):4199-4206. PubMed ID: 28654204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence.
    Pompe RS; Gild P; Karakiewicz PI; Bock LP; Schlomm T; Steuber T; Graefen M; Huland H; Tian Z; Tilki D
    Prostate; 2018 Jun; 78(9):676-681. PubMed ID: 29570821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):87-93. PubMed ID: 19918263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of prostate cancer biochemical recurrence and identification of disease persistence using PSA isoforms and human kallikrein-2.
    Do Carmo Silva J; Vesely S; Luksanova H; Prusa R; Babjuk M
    Tumour Biol; 2021; 43(1):197-207. PubMed ID: 34486998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database.
    Teeter AE; Sun L; Moul JW; Freedland SJ
    BJU Int; 2010 Sep; 106(6):796-800. PubMed ID: 20151967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
    Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal modeling of ultrasensitive and traditional prostate-specific antigen and prediction of biochemical recurrence after radical prostatectomy.
    Laajala TD; Seikkula H; Seyednasrollah F; Mirtti T; Boström PJ; Elo LL
    Sci Rep; 2016 Nov; 6():36161. PubMed ID: 27805011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Branche BL; Howard LE; Hamilton RJ; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Kane CJ;
    BJU Int; 2019 Jul; 124(1):69-75. PubMed ID: 30347135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.